Kyverna Therapeutics Inc (KYTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | |
| Assets | |||
| Current Assets | |||
| Cash & Cash Equivalents | 96,621 | 34,647 | 37,735 |
| Marketable Securities | 189,358 | 22,896 | 13,587 |
| TOTAL | $290,601 | $60,664 | $53,251 |
| Non-Current Assets | |||
| PPE Net | 3,347 | 2,326 | 2,575 |
| Other Non-Current Assets | 10,697 | 12,205 | 11,098 |
| TOTAL | $14,044 | $14,531 | $13,673 |
| Total Assets | $304,645 | $75,195 | $66,924 |
| Liabilities | |||
| Current Liabilities | |||
| Accounts payable and accrued liabilities | 4,624 | 4,358 | 1,451 |
| Accrued Expenses | 11,133 | 9,062 | 7,661 |
| Other current liabilities | N/A | N/A | 565 |
| TOTAL | $33,756 | $19,859 | $11,954 |
| Non-Current Liabilities | |||
| Other Non-Current Liabilities | 4,160 | 185,812 | 127,889 |
| TOTAL | $4,302 | $186,733 | $128,967 |
| Total Liabilities | $38,058 | $206,592 | $140,921 |
| Shareholders' Equity | |||
| Shares Outstanding, K | 43,215 | N/A | N/A |
| Retained earnings | -263,520 | -136,043 | -75,677 |
| Other shareholders' equity | 105 | 4 | -26 |
| TOTAL | $266,587 | $-131,397 | $-73,997 |
| Total Liabilities And Equity | $304,645 | $75,195 | $66,924 |